Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year
The vaccines are currently only authorised for emergency use in the country
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
The company has been manufacturing masks since the Covid-19 outbreak in 2020
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
The country is sixth among the most affected countries by active cases
Previously, the use of the drug was limited to patients requiring hospitalization
UCB plans to submit regulatory applications in Q3 2022
Subscribe To Our Newsletter & Stay Updated
